Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis

About 5% of chronic hepatitis C (CHC) patients experienced treatment failure with direct-acting antiviral (DAA) treatment. The global data on the practice and treatment outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in DAA-experienced CHC patients remains sparse. We performed a system...

Descripción completa

Detalles Bibliográficos
Autores principales: Devan, Pooja, Tiong, Kai Le Ashley, Neo, Jean Ee, Mohan, Babu P., Wijarnpreecha, Karn, Tam, Yew Chong Steve, Coppola, Nicola, Preda, Carmen Monica, Wong, Yu Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384139/
https://www.ncbi.nlm.nih.gov/pubmed/37515176
http://dx.doi.org/10.3390/v15071489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384139/
https://www.ncbi.nlm.nih.gov/pubmed/37515176
http://dx.doi.org/10.3390/v15071489

Ejemplares similares